查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1887995

全球抗体发现市场：按细分市场、技术、抗体类型、治疗领域、性质、最终用户和国家分類的分析和预测（2025-2035 年）

Antibody Discovery Market - A Global and Regional Analysis: Focus on Offering, Technology, Antibody Type, Therapeutics, Nature, End User, and Country - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 196 Pages | 商品交期: 1-5个工作天内

价格

全球抗体发现市场预计将从 2025 年的约 111.5 亿美元成长到 2035 年的 353.5 亿美元，复合年增长率约为 12.23%。

全球抗体发现市场正经历快速发展，工程技术、自动化和人工智慧的进步是推动这一成长的关键趋势之一。全人源和人源化抗体的研发正日益普及，它们能够提高治疗安全性、特异性和疗效，同时降低免疫抗原性。在噬菌体展示、基因改造动物模型和糖基化工程等技术的支持下，这些抗体研发模式正在革新癌症、自体免疫疾病和感染疾病的治疗方式。此外，高通量筛检、次世代定序和自动化技术的整合正在简化抗体鑑定和优化流程，显着缩短研发週期并提高成本效益。对合约研究组织（CRO）日益增长的依赖，为抗体筛检和工程改造提供了专业的基础设施和专业知识，进一步提升了扩充性并加速了创新。

关键市场统计数据
预测期 2025-2035
2025 年评估 111.5亿美元
2035 年预测 353.5亿美元
复合年增长率 12.23%

此外，人工智慧和机器学习正在透过实现预测建模、亲和性优化和快速序列设计，变革药物发现流程。这些工具提高了准确性并降低了研发成本，从而满足了日益增长的精准医疗需求。双特异性抗体、抗体药物复合体和单域抗体等创新技术正在扩展肿瘤学、免疫学和罕见疾病领域的治疗可能性。儘管面临高昂的生产成本以及来自基因疗法和细胞疗法等替代疗法的竞争等挑战，但自动化、生物资讯学和工艺扩充性的持续进步预计将在未来十年推动全球抗体发现市场的持续增长和技术成熟。

细分 1：按服务类别

以产品细分来看，产品细分占了较大的份额，其中包括发现工作流程中必不可少、高价值和经常性消费的产品，例如抗体发现平台和系统、试剂盒、试剂、抗体库等。服务也能带来可观的收入，但产品销售通常嵌入多个计划中，从而形成更广泛的收入基础。

细分2：依技术

从技术角度来看，噬菌体展示技术在抗体发现市场中占据主导地位，因为它能够对大规模的抗体库进行体外筛检，从而高效地分离针对各种复杂靶点的结合物。该技术无需免疫即可产生全人源抗体，使其成为製药公司、生技公司和其他终端用户应用最广泛的技术。

分段 3：按抗体类型

单株抗体在全球抗体发现市场中占最大份额，因为它们是一项成熟的技术，已获得广泛核准，并且是多种疾病领域治疗研发管线的基础。然而，双特异性抗体、抗体药物复合体（ADC）和其他改良型抗体具有更高的疗效和全新的作用机制，其快速的研发和临床成功使得新一代抗体成为成长最快的细分市场。

细分 4：按性质

由于人源抗体具有最高的生物相容性和最低的免疫抗原性风险，因此它们在生物製剂中占据最大份额。基因改造动物模型、噬菌体展示技术和单B细胞技术的进步，使得高效製备全人源抗体成为可能，使其成为安全持久治疗的最佳选择。

细分5：按治疗领域

按治疗领域划分，肿瘤治疗领域占最大份额，抗体已成为癌症治疗的基石，众多单株抗体、双特异性抗体和抗体药物复合体（ADC）核准或处于后期研发阶段。庞大的未满足医疗需求、大量的研发投入以及免疫肿瘤学领域对新一代抗体製剂的快速应用，共同支撑着该治疗领域的持续主导地位。

细分 6：按最终用户

从终端用户角度来看，製药和生物技术公司预计将在2024年占据大规模市场份额，因为它们进行广泛的内部研发，并拥有专有的发现平台，从而建立差异化的产品线。这些公司也积极与其他公司合作，加速抗体发现，同时利用授权协议和收购来扩展其治疗产品组合。它们雄厚的财力和对推进新一代抗体疗法开发的重视，进一步巩固了主导地位。

细分7：按地区

北美预计将占据全球抗体发现市场最大的份额，这主要得益于大型生物製药公司的强大实力、先进的研究基础设施和高额的研发投入。该地区受益于人工智慧驱动的发现平台的早期应用、广泛的临床试验活动以及有利于生物製药开发和商业化的法律规范。

本报告检视了全球抗体发现市场，并总结了关键趋势、市场影响因素分析、法律制度、研发管线分析、市场规模趋势和预测、按各个细分市场、地区/主要国家进行的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

范围和定义

第一章 市场：产业展望

  • 监管状态/合规性
    • 美国
    • EU
    • 亚太地区
    • 其他地区
  • 定价分析
    • 副产品
    • 按地区
  • 供应链分析
  • 价值链分析
  • 专利分析
    • 按国家/地区
    • 公司
    • 透过技术
  • 市场动态
    • 趋势、驱动因素、挑战和机会：评估当前和未来的影响

第二章规定类别

  • 供应类别：摘要
  • 抗体发现市场（按产品划分）
    • 抗体发现平台和系统
    • 试剂盒和试剂
    • 抗体库
    • 其他的
  • 抗体发现市场（按服务分类）
    • 抗原设计与製备
    • 热门製作和筛检
    • 线索筛选与优化
    • 抗体工程与表征
    • 其他的

第三章 技术

  • 技术摘要
  • 噬菌体展示技术
  • 融合瘤技术
  • 单B细胞技术
  • 基因改造动物方法
  • 其他技术

第四章 抗体类型

  • 抗体类型：摘要
  • 单株抗体（mAbs）
  • 多株抗体
  • 新一代抗体
    • 双特异性抗体
    • 抗体药物复合体（ADC）
    • 奈米抗体
    • 其他工程抗体

第五章 属性

  • 属性：摘要
  • 人类抗体
  • 人源化抗体
  • 嵌合体抗体
  • 小鼠抗体

第六章 治疗区

  • 治疗领域：摘要
  • 肿瘤性疾病
  • 免疫疾病
  • 感染疾病
  • 心血管疾病
  • 神经系统疾病
  • 其他的

第七章 最终用户

  • 最终用户：摘要
  • 製药和生物技术公司
  • 合约研究组织（CRO）
  • 学术研究机构
  • 其他的

第八章 区域

  • 区域：摘要
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
    • 区域概览
    • 市场成长驱动因素
    • 市场问题
    • 按供应类别
    • 透过技术
    • 按国家/地区

第九章 市场：竞争基准化分析与公司概况

  • 产品映射
  • 管道分析
  • 各公司的主要策略和发展
  • 公司简介
    • OmniAb Inc.
    • Twist Bioscience Corporation
    • Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    • WuXi Biologics (Cayman) Inc.
    • Charles River Laboratories International, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • FairJourney Biologics SA
    • Samsung Biologics
    • Genmab A/S
    • Alloy Therapeutics, Inc.

第十章调查方法

Product Code: BHL3199SA

This report can be delivered within 1 working day.

Global Antibody Discovery Market: Industry Overview

The global antibody discovery market was valued at approximately $11.15 billion in 2025 and is projected to grow $35.35 billion by 2035, at a CAGR of around 12.23%. The global antibody discovery market is rapidly evolving, driven by advancements in engineering technologies, automation, and artificial intelligence. A major trend shaping this growth is the shift toward fully human and humanized antibodies, which improve therapeutic safety, specificity, and efficacy while reducing immunogenicity. Supported by technologies such as phage display, transgenic animal models, and glycoengineering, these formats are transforming treatments for cancer, autoimmune, and infectious diseases. Additionally, the integration of high-throughput screening, next-generation sequencing, and automation has streamlined antibody identification and optimization, significantly shortening development timelines and improving cost efficiency. The increasing reliance on contract research organizations further enhances scalability and accelerates innovation by providing specialized infrastructure and expertise in antibody screening and engineering.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$11.15 Billion
2035 Forecast$35.35 Billion
CAGR12.23%

Additionally, artificial intelligence and machine learning are reshaping the discovery process by enabling predictive modeling, affinity optimization, and rapid sequence design. These tools enhance precision and reduce development costs, supporting the growing demand for precision therapies. Innovations such as bispecific antibodies, antibody-drug conjugates, and single-domain antibodies are broadening therapeutic potential across oncology, immunology, and rare diseases. Despite challenges such as high production costs and competition from alternative modalities such as gene and cell therapies, continued progress in automation, bioinformatics, and process scalability positions the global antibody discovery market for sustained growth and technological maturity in the coming decade.

Global Antibody Discovery Market Lifecycle Stage

The global antibody discovery market is positioned in the growth stage of its lifecycle, characterized by accelerating innovation, expanding adoption across therapeutic areas, and intensifying competition among established companies and emerging players. The market has evolved beyond early-stage scientific exploration into a mature, technology-driven ecosystem where efficiency, automation, and precision increasingly define competitive advantage. This phase is marked by the rapid integration of artificial intelligence and machine learning-enabled discovery platforms, high-throughput screening, and multi-omics integration, which are significantly reducing development timelines and enhancing candidate success rates.

As the market continues to mature, focus is shifting from innovation-driven discovery toward process optimization, clinical validation, and cost efficiency. Competitive dynamics are expected to intensify as new entrants leverage computational biology and synthetic biology approaches to challenge traditional discovery models. Over the next decade, the global antibody discovery market is anticipated to progress toward the early maturity phase, characterized by broader clinical adoption, standardized workflows, and increasing regulatory clarity.

Market Segmentation:

Segmentation 1: By Offering

  • Product
    • Antibody Discovery Platforms & Systems
    • Kits & Reagents
    • Antibody Libraries
    • Others
  • Services
    • Antigen Designing & Preparation
    • Hit Generation & Screening
    • Lead Selection & Optimization
    • Antibody Engineering & Characterization
    • Other Services

Products account for the larger share of the antibody discovery market as they include antibody discovery platforms and systems, kits, reagents, and antibody libraries, among others that are essential, high-value, and recurrently consumed across discovery workflows. While services generate significant revenue, product sales are often bundled into multiple projects, creating a broader revenue base.

Segmentation 2: By Technology

  • Phage Display Technology
  • Hybridoma Technology
  • Single B-Cell Technologies
  • Transgenic Animal-based Methods
  • Other Technologies

Phage display technology accounts for the largest share in the antibody discovery market as it allows the screening of very large antibody libraries in vitro, making it highly efficient for isolating binders against diverse and difficult targets. Its ability to generate fully human antibodies without the need for immunization has made it the most widely used technology by pharmaceutical and biotechnology companies and other end users.

Segmentation 3: By Antibody Type

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Next-Generation Antibodies
    • Bispecific Antibodies
    • Antibody-Drug Conjugates
    • Nanobodies
    • Other Engineered Antibodies

Monoclonal antibodies account for the largest share of the global antibody discovery market as they are well-established, widely approved, and form the backbone of therapeutic pipelines across multiple disease areas. However, next-generation antibodies are expected to be the fastest growing segment, driven by the rapid development and clinical success of bispecifics, ADCs, and other engineered formats that offer improved efficacy and novel mechanisms of action.

Segmentation 4: By Nature

  • Human Antibodies
  • Humanized Antibodies
  • Chimeric Antibodies
  • Murine Antibodies

Human antibodies hold the largest share in the antibody discovery market as they offer the highest compatibility and lowest risk of immunogenicity in patients. Advances in transgenic animal models, phage display, and single B-cell technologies have enabled efficient generation of fully human antibodies, making them the preferred choice as a safe and long-lasting therapeutics.

Segmentation 5: By Therapeutic Area

  • Oncological Disorders
  • Immunological Disorders
  • Infectious Diseases
  • Cardiovascular Disorders
  • Neurological Disorders
  • Other Therapeutic Areas

Oncology disorders account for the largest share of the antibody discovery market because antibodies have become a cornerstone of cancer therapy, with numerous monoclonal antibodies, bispecifics, and ADCs approved and in late-stage pipelines. The high unmet need, significant R&D investment, and rapid adoption of next-generation antibody formats in immuno-oncology drive sustained dominance of this therapeutic area.

Segmentation 6: By End User

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic and Research Institutes
  • Others

Based on end-user segmentation, pharmaceutical and biotechnology companies are expected to account for the largest share of the global antibody discovery market in 2024 as they conduct extensive in-house R&D and maintain proprietary discovery platforms to build differentiated pipelines. These companies also actively collaborate with others to accelerate antibody discovery, while leveraging licensing agreements and acquisitions to expand their therapeutic portfolios. Their strong financial capacity and emphasis on advancing next-generation antibody modalities further reinforce their leading role in this market.

Segmentation 7: By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

North America is expected to hold the largest share of the global antibody discovery market, driven by the strong presence of major biopharmaceutical companies, advanced research infrastructure, and high R&D investments. The region benefits from early adoption of AI-driven discovery platforms, extensive clinical trial activity, and supportive regulatory frameworks that accelerate biologics development and commercialization.

Demand - Drivers and Limitations

Demand Drivers for the Global Antibody Discovery Market:

  • Advancements in Antibody Engineering for Therapeutic Applications
  • Increasing Prevalence of Chronic Diseases

Limitations for the Global Antibody Discovery Market:

  • Rising Shift toward Alternative Antibody-Based Treatment Modalities
  • High Costs Restrict Widespread Adoption of Antibody Therapies

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the global antibody discovery market, focusing on innovation-driven growth across discovery platforms, engineering technologies, and therapeutic applications. It guides R&D investment strategies, technology adoption, and pipeline optimization, allowing companies to prioritize initiatives that accelerate lead identification, candidate validation, and antibody optimization.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the antibody discovery ecosystem.

Key Market Players and Competitive Landscape

The global antibody discovery market is characterized by a rapidly evolving and competitive landscape, driven by technological innovation, strategic partnerships, and the growing demand for next-generation therapeutics. The market comprises a mix of well-established biopharmaceutical companies and emerging biotechnology firms specializing in advanced discovery platforms, contract research services, and integrated biologics development as well as contract research organizations. Key players include:

  • OmniAb Inc.
  • Twist Bioscience Corporation
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
  • WuXi Biologics Inc.
  • Charles River Laboratories International, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • FairJourney Biologics S.A.
  • Samsung Biologics
  • Genmab A/S
  • Alloy Therapeutics, Inc.

Competitive benchmarking highlights mergers and acquisitions, funding activities, licensing deals, and collaborations with pharmaceutical organizations, reflecting the growing emphasis on innovation and speed-to-market. Companies are evaluated based on market presence, technological capabilities, strategic initiatives, and product portfolios. Detailed company profiles cover target end users, technological focus areas, and expert analyst perspectives, providing stakeholders with actionable insights into investment opportunities, market positioning, and strategic growth pathways. This intelligence enables organizations to effectively align their R&D and commercialization strategies with emerging market dynamics of the global antibody discovery market.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

  • 1.1 Regulatory Landscape / Compliance
    • 1.1.1 U.S.
    • 1.1.2 E.U.
      • 1.1.2.1 Germany
      • 1.1.2.2 France
      • 1.1.2.3 Italy
    • 1.1.3 Asia-Pacific
      • 1.1.3.1 China
      • 1.1.3.2 Japan
    • 1.1.4 Rest-of-the-World
      • 1.1.4.1 Brazil
      • 1.1.4.2 U.A.E.
  • 1.2 Pricing Analysis
    • 1.2.1 By Product
    • 1.2.2 By Region
  • 1.3 Supply Chain Analysis
  • 1.4 Value Chain Analysis
  • 1.5 Patent Analysis
    • 1.5.1 By Country
    • 1.5.2 By Company
    • 1.5.3 By Technology
  • 1.6 Market Dynamics
    • 1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
    • 1.6.2 Market Trends
      • 1.6.2.1 Shift toward Fully Human and Humanized Antibodies
      • 1.6.2.2 Increasing Reliance on High-Throughput Screening and Automation
      • 1.6.2.3 Growing Role of Contract Research Organizations (CROs)
    • 1.6.3 Market Drivers
      • 1.6.3.1 Advancements in Antibody Engineering for Therapeutic Applications
      • 1.6.3.2 Increasing Prevalence of Chronic Diseases
    • 1.6.4 Market Challenges
      • 1.6.4.1 Rising Shift Toward Alternative Antibody-Based Treatment Modalities
      • 1.6.4.2 High Costs Restrict Widespread Adoption of Antibody Therapies
    • 1.6.5 Market Opportunities
      • 1.6.5.1 Integration of Artificial Intelligence and Machine Learning in Antibody Discovery

2 Offering

  • 2.1 Offering Summary
  • 2.2 Antibody Discovery Market (by Products)
    • 2.2.1 Antibody Discovery Platforms and Systems
    • 2.2.2 Kits and Reagents
    • 2.2.3 Antibody Libraries
    • 2.2.4 Other Products
  • 2.3 Antibody Discovery Market (by Services)
    • 2.3.1 Antigen Designing and Preparation
    • 2.3.2 Hit Generation and Screening
    • 2.3.3 Lead Selection and Optimization
    • 2.3.4 Antibody Engineering and Characterization
    • 2.3.5 Other Services

3 Technology

  • 3.1 Technology Summary
  • 3.2 Phage Display Technology
  • 3.3 Hybridoma Technology
  • 3.4 Single B-Cell Technologies
  • 3.5 Transgenic Animal-Based Methods
  • 3.6 Other Technologies

4 Antibody Type

  • 4.1 Antibody Type Summary
  • 4.2 Monoclonal Antibodies (mAbs)
  • 4.3 Polyclonal Antibodies
  • 4.4 Next-Generation Antibodies
    • 4.4.1 Bispecific Antibodies
    • 4.4.2 Antibody-Drug Conjugates (ADCs)
    • 4.4.3 Nanobodies
    • 4.4.4 Other Engineered Antibodies

5 Nature

  • 5.1 Nature Summary
  • 5.2 Human Antibodies
  • 5.3 Humanized Antibodies
  • 5.4 Chimeric Antibodies
  • 5.5 Murine Antibodies

6 Therapeutic Area

  • 6.1 Therapeutic Area Summary
  • 6.2 Oncological Disorders
  • 6.3 Immunological Disorders
  • 6.4 Infectious Diseases
  • 6.5 Cardiovascular Disorders
  • 6.6 Neurological Disorders
  • 6.7 Other Therapeutic Areas

7 End User

  • 7.1 End User Summary
  • 7.2 Pharmaceutical and Biotechnology Companies
  • 7.3 Contract Research Organizations (CROs)
  • 7.4 Academic and Research Institutes
  • 7.5 Others

8 Region

  • 8.1 Regional Summary
  • 8.2 North America
    • 8.2.1 Regional Overview
    • 8.2.2 Driving Factors for Market Growth
    • 8.2.3 Factors Challenging the Market
    • 8.2.4 By Offering
    • 8.2.5 By Technology
    • 8.2.6 By Country
      • 8.2.6.1 U.S.
        • 8.2.6.1.1 By Offering
        • 8.2.6.1.2 By Technology
      • 8.2.6.2 Canada
        • 8.2.6.2.1 By Offering
        • 8.2.6.2.2 By Technology
  • 8.3 Europe
    • 8.3.1 Regional Overview
    • 8.3.2 Driving Factors for Market Growth
    • 8.3.3 Factors Challenging the Market
    • 8.3.4 By Offering
    • 8.3.5 By Technology
    • 8.3.6 By Country
      • 8.3.6.1 U.K.
        • 8.3.6.1.1 By Offering
        • 8.3.6.1.2 By Technology
      • 8.3.6.2 Germany
        • 8.3.6.2.1 By Offering
        • 8.3.6.2.2 By Technology
      • 8.3.6.3 France
        • 8.3.6.3.1 By Offering
        • 8.3.6.3.2 By Technology
      • 8.3.6.4 Italy
        • 8.3.6.4.1 By Offering
        • 8.3.6.4.2 By Technology
      • 8.3.6.5 Spain
        • 8.3.6.5.1 By Offering
        • 8.3.6.5.2 By Technology
      • 8.3.6.6 Sweden
        • 8.3.6.6.1 By Offering
        • 8.3.6.6.2 By Technology
      • 8.3.6.7 Netherlands
        • 8.3.6.7.1 By Offering
        • 8.3.6.7.2 By Technology
      • 8.3.6.8 Rest-of-Europe
        • 8.3.6.8.1 By Offering
        • 8.3.6.8.2 By Technology
  • 8.4 Asia-Pacific
    • 8.4.1 Regional Overview
    • 8.4.2 Driving Factors for Market Growth
    • 8.4.3 Factors Challenging the Market
    • 8.4.4 By Offering
    • 8.4.5 By Technology
    • 8.4.6 By Country
      • 8.4.6.1 Japan
        • 8.4.6.1.1 By Offering
        • 8.4.6.1.2 By Technology
      • 8.4.6.2 China
        • 8.4.6.2.1 By Offering
        • 8.4.6.2.2 By Technology
      • 8.4.6.3 India
        • 8.4.6.3.1 By Offering
        • 8.4.6.3.2 By Technology
      • 8.4.6.4 Australia
        • 8.4.6.4.1 By Offering
        • 8.4.6.4.2 By Technology
      • 8.4.6.5 South Korea
        • 8.4.6.5.1 By Offering
        • 8.4.6.5.2 By Technology
      • 8.4.6.6 Singapore
        • 8.4.6.6.1 By Offering
        • 8.4.6.6.2 By Technology
      • 8.4.6.7 Rest-of-Asia-Pacific
        • 8.4.6.7.1 By Offering
        • 8.4.6.7.2 By Technology
  • 8.5 Latin America
    • 8.5.1 Regional Overview
    • 8.5.2 Driving Factors for Market Growth
    • 8.5.3 Factors Challenging the Market
    • 8.5.4 By Offering
    • 8.5.5 By Technology
    • 8.5.6 By Country
      • 8.5.6.1 Brazil
        • 8.5.6.1.1 By Offering
        • 8.5.6.1.2 By Technology
      • 8.5.6.2 Mexico
        • 8.5.6.2.1 By Offering
        • 8.5.6.2.2 By Technology
      • 8.5.6.3 Argentina
        • 8.5.6.3.1 By Offering
        • 8.5.6.3.2 By Technology
      • 8.5.6.4 Rest-of-Latin America
        • 8.5.6.4.1 By Offering
        • 8.5.6.4.2 By Technology
  • 8.6 Middle East and Africa
    • 8.6.1 Regional Overview
    • 8.6.2 Driving Factors for Market Growth
    • 8.6.3 Factors Challenging the Market
    • 8.6.4 By Offering
    • 8.6.5 By Technology
    • 8.6.6 By Country
      • 8.6.6.1 K.S.A.
        • 8.6.6.1.1 By Offering
        • 8.6.6.1.2 By Technology
      • 8.6.6.2 U.A.E.
        • 8.6.6.2.1 By Offering
        • 8.6.6.2.2 By Technology
      • 8.6.6.3 Rest of-Middle East and Africa
        • 8.6.6.3.1 By Offering
        • 8.6.6.3.2 By Technology

9 Markets - Competitive Benchmarking & Company Profiles

  • 9.1 Product Mapping
    • 9.1.1 By Company
    • 9.1.2 By Offering
    • 9.1.3 By Technology
  • 9.2 Pipeline Analysis
  • 9.3 Key Strategies and Developments by Company
    • 9.3.1 Funding Activities
    • 9.3.2 Mergers and Acquisitions
    • 9.3.3 Regulatory Approvals and Product Launches
    • 9.3.4 Partnerships, Collaborations, and Business Expansions
  • 9.4 Company Profiles
    • 9.4.1 OmniAb Inc.
      • 9.4.1.1 Overview
      • 9.4.1.2 Top Products/Product Portfolio
      • 9.4.1.3 Top Competitors
      • 9.4.1.4 Target Customers
      • 9.4.1.5 Key Personal
      • 9.4.1.6 Analyst View
    • 9.4.2 Twist Bioscience Corporation
      • 9.4.2.1 Overview
      • 9.4.2.2 Top Products/Product Portfolio
      • 9.4.2.3 Top Competitors
      • 9.4.2.4 Target Customers
      • 9.4.2.5 Key Personal
      • 9.4.2.6 Analyst View
    • 9.4.3 Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
      • 9.4.3.1 Overview
      • 9.4.3.2 Top Products/Product Portfolio
      • 9.4.3.3 Top Competitors
      • 9.4.3.4 Target Customers
      • 9.4.3.5 Key Personal
      • 9.4.3.6 Analyst View
    • 9.4.4 WuXi Biologics (Cayman) Inc.
      • 9.4.4.1 Overview
      • 9.4.4.2 Top Products/Product Portfolio
      • 9.4.4.3 Top Competitors
      • 9.4.4.4 Target Customers
      • 9.4.4.5 Key Personal
      • 9.4.4.6 Analyst View
    • 9.4.5 Charles River Laboratories International, Inc.
      • 9.4.5.1 Overview
      • 9.4.5.2 Top Products/Product Portfolio
      • 9.4.5.3 Top Competitors
      • 9.4.5.4 Target Customers
      • 9.4.5.5 Key Personal
      • 9.4.5.6 Analyst View
    • 9.4.6 Regeneron Pharmaceuticals, Inc.
      • 9.4.6.1 Overview
      • 9.4.6.2 Top Products/Product Portfolio
      • 9.4.6.3 Top Competitors
      • 9.4.6.4 Target Customers
      • 9.4.6.5 Key Personal
      • 9.4.6.6 Analyst View
    • 9.4.7 FairJourney Biologics S.A.
      • 9.4.7.1 Overview
      • 9.4.7.2 Top Products/Product Portfolio
      • 9.4.7.3 Top Competitors
      • 9.4.7.4 Target Customers
      • 9.4.7.5 Key Personal
      • 9.4.7.6 Analyst View
    • 9.4.8 Samsung Biologics
      • 9.4.8.1 Overview
      • 9.4.8.2 Top Products/Product Portfolio
      • 9.4.8.3 Top Competitors
      • 9.4.8.4 Target Customers
      • 9.4.8.5 Key Personal
      • 9.4.8.6 Analyst View
    • 9.4.9 Genmab A/S
      • 9.4.9.1 Overview
      • 9.4.9.2 Top Products/Product Portfolio
      • 9.4.9.3 Top Competitors
      • 9.4.9.4 Target Customers
      • 9.4.9.5 Key Personal
      • 9.4.9.6 Analyst View
    • 9.4.10 Alloy Therapeutics, Inc.
      • 9.4.10.1 Overview
      • 9.4.10.2 Top Products/Product Portfolio
      • 9.4.10.3 Top Competitors
      • 9.4.10.4 Target Customers
      • 9.4.10.5 Key Personal
      • 9.4.10.6 Analyst View

10 Research Methodology

  • 10.1 Data Sources
    • 10.1.1 Primary Data Sources
    • 10.1.2 Secondary Data Sources
    • 10.1.3 Data Triangulation
  • 10.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Antibody Discovery Market (by Scenario), $Billion, 2024, 2030, and 2035
  • Figure 2: Global Antibody Discovery Market (by Region), $Billion, 2024 and 2035
  • Figure 3: Global Antibody Discovery Market (by Offering), $Billion, 2024, 2030, and 2035
  • Figure 4: Global Antibody Discovery Market (by Technology), $Billion, 2024, 2030, and 2035
  • Figure 5: Global Antibody Discovery Market (by AntibodyType), $Billion, 2024, 2030, and 2035
  • Figure 6: Global Antibody Discovery Market (by Nature), $Billion, 2024, 2030, and 2035
  • Figure 7: Global Antibody Discovery Market (by Therapeutic Area), $Billion, 2024, 2030, and 2035
  • Figure 8: Global Antibody Discovery Market (by End User), $Billion, 2024, 2030, and 2035
  • Figure 9: Global Antibody Discovery Market, Value Chain Analysis
  • Figure 10: Global Antibody Discovery Market, Patent Analysis (by Country), January 2022- August 2025
  • Figure 11: Global Antibody Discovery Market, Patent Analysis (by Company), January 2022- August 2025
  • Figure 12: Global Antibody Discovery Market, Patent Analysis (by Technology), January 2022- August 2025
  • Figure 13: Global Antibody Discovery Market (by Offering), $Billion, 2024, 2030, and 2035
  • Figure 14: Global Antibody Discovery Market (Antibody Discovery Platforms and Systems), $Billion, 2024-2035
  • Figure 15: Global Antibody Discovery Market (Kits and Reagents), $Billion, 2024-2035
  • Figure 16: Global Antibody Discovery Market (Antibody Libraries), $Billion, 2024-2035
  • Figure 17: Global Antibody Discovery Market (Other Products), $Billion, 2024-2035
  • Figure 18: Global Antibody Discovery Market (Antigen Designing and Preparation), $Billion, 2024-2035
  • Figure 19: Global Antibody Discovery Market (Hit Generation and Screening), $Billion, 2024-2035
  • Figure 20: Global Antibody Discovery Market (Lead Selection and Optimization), $Billion, 2024-2035
  • Figure 21: Global Antibody Discovery Market (Antibody Engineering and Characterization), $Billion, 2024-2035
  • Figure 22: Global Antibody Discovery Market (Other Services), $Billion, 2024-2035
  • Figure 23: Global Antibody Discovery Market (by Technology), $Billion, 2024, 2030, and 2035
  • Figure 24: Global Antibody Discovery Market (Phage Display Technology), $Billion, 2024-2035
  • Figure 25: Global Antibody Discovery Market (Hybridoma Technology), $Billion, 2024-2035
  • Figure 26: Global Antibody Discovery Market (Single B-Cell Technologies), $Billion, 2024-2035
  • Figure 27: Global Antibody Discovery Market (Transgenic Animal-Based Methods), $Billion, 2024-2035
  • Figure 28: Global Antibody Discovery Market (Other Technologies), $Billion, 2024-2035
  • Figure 29: Global Antibody Discovery Market (by Antibody Type), $Billion, 2024, 2030, and 2035
  • Figure 30: Global Antibody Discovery Market (Monoclonal Antibodies (mAbs)), $Billion, 2024-2035
  • Figure 31: Global Antibody Discovery Market (Polyclonal Antibodies), $Billion, 2024-2035
  • Figure 32: Global Antibody Discovery Market (Next-Generation Antibodies), $Billion, 2024-2035
  • Figure 33: Global Antibody Discovery Market (Bispecific Antibodies), $Billion, 2024-2035
  • Figure 34: Global Antibody Discovery Market (Antibody-Drug Conjugates(ADCs)), $Billion, 2024-2035
  • Figure 35: Global Antibody Discovery Market (Nanobodies), $Billion, 2024-2035
  • Figure 36: Global Antibody Discovery Market (Other Engineered Antibodies), $Billion, 2024-2035
  • Figure 37: Global Antibody Discovery Market (by Nature), $Billion, 2024-2035
  • Figure 38: Global Antibody Discovery Market (Human Antibodies), $Billion, 2024-2035
  • Figure 39: Global Antibody Discovery Market (Humanized Antibodies), $Billion, 2024-2035
  • Figure 40: Global Antibody Discovery Market (Chimeric Antibodies), $Billion, 2024-2035
  • Figure 41: Global Antibody Discovery Market (Murine Antibodies), $Billion, 2024-2035
  • Figure 42: Global Antibody Discovery Market (by Therapeutic Area), $Billion, 2024-2035
  • Figure 43: Global Antibody Discovery Market (Oncological Disorders), $Billion, 2024-2035
  • Figure 44: Global Antibody Discovery Market (Immunological Disorders), $Billion, 2024-2035
  • Figure 45: Global Antibody Discovery Market (Infectious Diseases), $Billion, 2024-2035
  • Figure 46: Global Antibody Discovery Market (Cardiovascular Disorders), $Billion, 2024-2035
  • Figure 47: Global Antibody Discovery Market (Neurological Disorders), $Billion, 2024-2035
  • Figure 48: Global Antibody Discovery Market (Other Therapeutic Areas), $Billion, 2024-2035
  • Figure 49: Global Antibody Discovery Market (by End User), $Billion, 2024, 2030, and 2035
  • Figure 50: Global Antibody Discovery Market (Pharmaceutical and Biotechnology Companies), $Billion, 2024-2035
  • Figure 51: Global Antibody Discovery Market (Contract Research Organizations(CROs)), $Billion, 2024-2035
  • Figure 52: Global Antibody Discovery Market (Academic and Research Institutes), $Billion, 2024-2035
  • Figure 53: Global Antibody Discovery Market (Others), $Billion, 2024-2035
  • Figure 54: U.S. Antibody Discovery Market, $Billion, 2024-2035
  • Figure 55: Canada Antibody Discovery Market, $Billion, 2024-2035
  • Figure 56: Europe Antibody Discovery Market, $Billion, 2024-2035
  • Figure 57: U.K. Antibody Discovery Market, $Billion, 2024-2035
  • Figure 58: Germany Antibody Discovery Market, $Billion, 2024-2035
  • Figure 59: France Antibody Discovery Market, $Billion, 2024-2035
  • Figure 60: Italy Antibody Discovery Market, $Billion, 2024-2035
  • Figure 61: Spain Antibody Discovery Market, $Billion, 2024-2035
  • Figure 62: Sweden Antibody Discovery Market, $Billion, 2024-2035
  • Figure 63: nds Antibody Discovery Market, $Billion, 2024-2035
  • Figure 64: Rest-of-Europe Antibody Discovery Market, $Billion, 2024-2035
  • Figure 65: Japan Antibody Discovery Market, $Billion, 2024-2035
  • Figure 66: China Antibody Discovery Market, $Billion, 2024-2035
  • Figure 67: India Antibody Discovery Market, $Billion, 2024-2035
  • Figure 68: Australia Antibody Discovery Market, $Billion, 2024-2035
  • Figure 69: South Korea Antibody Discovery Market, $Billion, 2024-2035
  • Figure 70: Singapore Antibody Discovery Market, $Billion, 2024-2035
  • Figure 71: Rest-of-Asia-Pacific Antibody Discovery Market, $Billion, 2024-2035
  • Figure 72: Brazil Antibody Discovery Market, $Billion, 2024-2035
  • Figure 73: Mexico Antibody Discovery Market, $Billion, 2024-2035
  • Figure 74: Mexico Antibody Discovery Market, $Billion, 2024-2035
  • Figure 75: Rest-of-Latin America Antibody Discovery Market, $Billion, 2024-2035
  • Figure 76: K.S.A. Antibody Discovery Market, $Billion, 2024-2035
  • Figure 77: U.A.E. Antibody Discovery Market, $Billion, 2024-2035
  • Figure 78: Rest-of-Middle East and Africa Antibody Discovery Market, $Billion, 2024-2035
  • Figure 79: Global Antibody Discovery Market, Product Mapping (by Company)
  • Figure 80: Data Triangulation
  • Figure 81: Top-Down and Bottom-Up Approach
  • Figure 82: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Pricing Analysis (by Region)
  • Table 3: Antibody Discovery Market (by Region), $Billion, 2024-2035
  • Table 4: North America Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 5: North America Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 6: U.S. Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 7: U.S. Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 8: Canada Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 9: Canada Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 10: Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 11: Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 12: U.K. Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 13: U.K. Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 14: Germany Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 15: Germany Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 16: France Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 17: France Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 18: Italy Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 19: Italy Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 20: Spain Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 21: Spain Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 22: Sweden Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 23: Sweden Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 24: Netherlands Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 25: Netherlands Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 26: Rest-of-Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 27: Rest-of-Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 28: Asia-Pacific Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 29: Asia-Pacific Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 30: Japan Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 31: Japan Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 32: China Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 33: China Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 34: India Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 35: India Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 36: Australia Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 37: Australia Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 38: South Korea Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 39: South Korea Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 40: Singapore Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 41: Singapore Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 42: Rest-of-Asia-Pacific Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 43: Rest-of-Asia-Pacific Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 44: Latin America Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 45: Latin America Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 46: Brazil Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 47: Brazil Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 48: Mexico Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 49: Mexico Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 50: Argentina Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 51: Argentina Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 52: Rest-of-Latin America Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 53: Rest-of-Latin America Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 54: Middle East and Africa Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 55: Middle East and Africa Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 56: K.S.A. Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 57: K.S.A. Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 58: U.A.E. Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 59: U.A.E. Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 60: Rest-of-Middle East and Africa Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 61: Rest-of-Middle East and Africa Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 62: Global Antibody Discovery Market, Product Mapping (by Offering)
  • Table 63: Global Antibody Discovery Market
  • Table 64: Pipeline Analysis